Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) have earned an average recommendation of “Hold” from the nine research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $13.75.

JNCE has been the subject of a number of analyst reports. Zacks Investment Research cut Jounce Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 2nd. Cowen reissued a “hold” rating on shares of Jounce Therapeutics in a report on Tuesday, November 13th. HC Wainwright set a $13.00 price objective on Jounce Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 14th. Finally, JPMorgan Chase & Co. cut Jounce Therapeutics from a “neutral” rating to an “underweight” rating in a report on Tuesday, November 13th.

Shares of NASDAQ JNCE traded up $0.18 during midday trading on Friday, reaching $4.26. 5,055 shares of the company traded hands, compared to its average volume of 154,237. The stock has a market cap of $137.34 million, a PE ratio of -7.44 and a beta of 3.80. Jounce Therapeutics has a 12 month low of $2.66 and a 12 month high of $29.25.

Institutional investors have recently added to or reduced their stakes in the stock. Creative Planning bought a new position in shares of Jounce Therapeutics in the third quarter valued at about $143,000. BlackRock Inc. raised its holdings in shares of Jounce Therapeutics by 22.2% in the second quarter. BlackRock Inc. now owns 1,394,905 shares of the company’s stock valued at $10,684,000 after buying an additional 253,120 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Jounce Therapeutics in the third quarter valued at about $677,000. Schwab Charles Investment Management Inc. raised its holdings in shares of Jounce Therapeutics by 20.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 47,951 shares of the company’s stock valued at $368,000 after buying an additional 8,103 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Jounce Therapeutics by 153.0% in the third quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock valued at $2,861,000 after buying an additional 266,126 shares during the last quarter. 82.63% of the stock is owned by institutional investors and hedge funds.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

See Also: Economic Reports

Analyst Recommendations for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.